The estimated national burden of C. difficile infections and associated hospitalizations decreased from 2011 through 2017 by approx. 24%, owing to a decline in health care-associated infections.
Patients with any polyps in a largely screening-naive population of Sweden had a higher colorectal cancer incidence as compared to individuals from the general population. Moreover, patients with sessile serrated polyps, tubulovillous or villous adenomas had a higher colorectal cancer mortality.
In a current study, more than one third of patients admitted to the hospital with SARS-CoV-2 infection had abnormal liver enzymes. This was associated with longer hospital stay. In addition, treatment with lopinavir/ritonavir was associated with increased liver enzymes; these drugs should be given with caution.
In patients with unresectable HCC, atezolizumab combined with bevacizumab resulted in better overall and progressionfree survival outcomes than sorafenib. In this current phase 3 trial, 12 months overall survival was 55% with sorafenib and 67% with atezolizumab-bevacizumab. Grad 3 and 4 adverse events occurred with the same frequency with sorafenib and atezolizumab-bevacizumab, respectively.
Oesophagus Stomach Duodenum
Results of this randomized trial indicate that recurrent bleeding rates in patients with a history of bleeding from Helicobacter pylori-negative ulcers are comparable between users of lansoprazole and famotidine over 24 months.
Results of a placebo-controlled pilot trial suggest that FMT is well tolerated and results in sustained changes of the intestinal microbiota and bile acid profiles, but does not affect the body mass index in obese metabolically uncompromised patients.
Patients with acute pancreatitis and coexisting SARS-CoV-2 infection were at increased risk of severe pancreatitis disease course, worse clinical outcomes, prolonged hospital stay and high 30-day mortality in a prospective multicenter cohort study.